跳至主要内容
临床试验/NCT00206089
NCT00206089终止3 期

The "EXTEND" Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery.

AstraZeneca125 个研究点 分布在 8 个国家目标入组 3,300 人开始时间: 2005年9月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
终止
发起方
AstraZeneca
入组人数
3,300
试验地点
125
主要终点
Non-inferiority for the prevention of VTE or VTE related death

研究概览

简要总结

This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks. A separate visit, independent from the study will be done approximately 6 months after the surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent,
  • Female or male aged 18 years and over
  • Patient scheduled for primary elective hip replacement or patient requiring surgery for hip fracture.

排除标准

  • History of heparin-induced thrombocytopenia
  • Conditions associated with increased risk of bleeding, renal impairment, known active liver disease or liver insufficiency.
  • Myocardial infarction, Ischemic stroke or Transient Ischemic Attack (TIA), systemic embolism or venous thrombo-embolism within 30 days of enrollment.

结局指标

主要结局

Non-inferiority for the prevention of VTE or VTE related death

次要结局

  • Superiority regarding major bleeding or the percentage of patients requiring donor blood transfusion.
  • Safety

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (125)

Loading locations...

相似试验